NOX-H94

DRUG3 trials

Sponsors

TME Pharma AG

Conditions

AnemiaAnemia of Chronic DiseaseChronic DiseasesInflammation

Phase 1

First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94

CompletedNCT01372137

TME Pharma AGAnemia, Chronic Diseases, Inflammation

Start: 2011-07-31End: 2012-03-31Updated: 2016-01-25

Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model

CompletedNCT01522794

TME Pharma AGAnemia of Chronic Disease

Start: 2012-01-31End: 2012-04-30Updated: 2014-11-10

Phase 2

Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

CompletedNCT01691040

TME Pharma AGAnemia of Chronic Disease

Start: 2012-09-30End: 2013-12-31Updated: 2014-06-26

Related Papers

Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans

Blood2014-08-28109 citations